SGLT2-hæmning til kronisk nyresygdom uden ledsagende diabetes eller hjertesvigt

Research output: Contribution to journalReviewResearchpeer-review


  • Fulltext

    Final published version, 444 KB, PDF document

This review summarises the current knowledge of electroconvulsive therapy (ECT) which is still the most potent and fast-acting antidepressant intervention. The modern procedure is safe when general precautions are taken. Cognitive side effects are transient in most patients, and concerns about side effects should not prevent relevant use. Due to the prognostic benefits of rapid remission, ECT should, in relevant patients, be considered early in the treatment course. Patients should be offered maintenance pharmacotherapy, and, in high-risk cases, tapering of the acute ECT course or maintenance ECT, in order to reduce the risk of relapse.

Translated title of the contributionSGLT2 inhibitorsfor treatment of chronic kidney disease without diabetes or heart failure
Original languageDanish
Article numberV11210887
JournalUgeskrift for Laeger
Issue number16
Number of pages8
Publication statusPublished - 18 Apr 2022

ID: 327138264